Top

Published in:

01-03-2017 | Original Paper

Immunolocalization of substance P and NK-1 receptor in vascular anomalies

Authors: Alejandro Ortiz-Prieto, José Bernabeu-Wittel, Teresa Zulueta-Dorado, Ana I. Lorente-Lavirgen, Miguel Muñoz

Published in: Archives of Dermatological Research | Issue 2/2017

Abstract

The peptide substance P (SP) shows a widespread distribution in both the central and peripheral nervous systems, but it is also ubiquitous in the human body. After binding to the neurokinin-1 (NK-1) receptor, SP regulates tumoral angiogenesis and proliferation. Thus, knowledge of this system is the key for a better understanding and, hence, a better management of many human diseases, including vascular anomalies (VA). This study aims to examine the expression and localization of both SP and the NK-1 receptor in different vascular anomalies using an immunohistochemical technique. Our results demonstrated predominantly nuclear localization of SP in venous malformations and in one haemangioma sample, in contrast with cytoplasmic expression in capillary malformations and rapidly involuting congenital hemangioma (RICH). NK-1 receptor showed a cytoplasmic localization in all VA. In summary, all these findings demonstrate that SP and NK-1 receptor are expressed in VA, with different expression patterns depending on the nature of the anomaly, suggesting that they could play an important role in the pathogenesis of VA.

Aliakbari J, Sreedharan SP, Turck CW et al (1987) Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. Biochem Biophys Res Commun 148:1440–1445CrossRefPubMed

Berger M, Neth O, Ilmer M et al (2014) Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol 60:985–994CrossRefPubMed

Bielenberg DR, Bucana CD, Sanchez R et al (1999) Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 14:401–408PubMed

Böckle BC, Sölder E, Kind S et al (2008) DC-SIGN + CD163 + Macrophages Expressing Hyaluronan Receptor LYVE-1 Are Located within Chorion Villi of the Placenta. Placenta 29:187–192CrossRefPubMed

Boscolo E, Bischoff J (2009) Vasculogenesis in infantile hemangioma. Angiogenesis 12:197–207CrossRefPubMedPubMedCentral

Brener S, González-Moles MA, Tostes D et al (2009) A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 29:2323–2329PubMed

Castellani ML, Galzio RJ, Felaco P et al (2010) VEGF, substance P and stress, new aspects: a revisited study. J Biol Regul Homeost Agents 24(3):229–237PubMed

Chiwakata C, Brackmann B, Hunt N et al (1991) Tachykinin (substance-P) gene expression in Leydig cells of the human and mouse testis. Endocrinology 128:2441–2448CrossRefPubMed

Demir R, Seval Y, Huppertz B (2007) Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem 109:257–265CrossRefPubMed

10.

Esteban F, González-Moles MA, Castro D et al (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54:258–260CrossRefPubMed

11.

Garzon MC, Huang JT, Enjolras O et al (2007) Vascular malformations: Part II: associated syndromes. J Am Acad Dermatol 56:541–564CrossRefPubMed

12.

González-Moles MA, Mosqueda-Taylor A, Esteban F et al (2008) Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol 44:1127–1133CrossRefPubMed

13.

Guha S, Eibl G, Kisfalvi K et al (2005) Broad-spectrum G protein–coupled receptor antagonist, [D-Arg1, DTrp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65:2738–2745CrossRefPubMed

14.

Hennig IM, Laissue JA, Horisberger U et al (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792CrossRefPubMed

15.

International Society for the Study of Vascular Anomalies (2014) ISSVA Classification of vascular anomalies. In: Classification. International Society for the Study of Vascular Anomalies. www.issva.org/classification. Accessed Apr 2014

16.

Jang JH, Nam TS, Paik KS et al (2004) Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumaticneuropathy model of the rat. Neurosci Lett 360:129–132CrossRefPubMed

17.

Koh YH, Tamizhselvi R, Bhatia M (2010) Extracellular signalregulated kinase 1/2 and c-Jun NH2-terminal kinase, through nuclear factor-kappaB and activator protein-1, contribute to caerulein-induced expression of substance P and neurokinin-1 receptors in pancreatic acinar cells. J Pharmacol Exp Ther 332:940–948CrossRefPubMed

18.

Lai JP, Douglas SD, Ho WZ (1998) Human lymphocytes express substance P and its receptor. J Neuroimmunol 86:80–86CrossRefPubMed

19.

Linnik MD, Moskowitz MA (1989) Identification of immunoreactive substance P in human and other mammalian endothelial cells. Peptides 10:957–962CrossRefPubMed

20.

Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56:4983–4991PubMed

21.

Milner P, Kirkpatrick KA, Ralevic V et al (1990) Endothelial cells cultured from human umbilical vein release ATP, substance P and acetylcholine in response to increased flow. Proc Biol Sci 241:245–248CrossRefPubMed

22.

Muñoz M, Bernabeu-Wittel J, Coveñas R (2011) NK-1 as a melanoma target. Expert Opinion Therapeutic Targets 15:889–897CrossRef

23.

Muñoz M, Carranza A, Pavón A et al (2013) Immunolocalization of substance P and NK-1 receptor in hofbauer cells in human normal placenta. Microsc Res Tech 76:1310–1313CrossRefPubMed

24.

Muñoz M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504–516CrossRefPubMed

25.

Muñoz M, Coveñas R (2011) NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 18:1820–1831CrossRefPubMed

26.

Muñoz M, Coveñas R (2013) Involvement of substance P and the NK-1 receptor in cancer. Peptides 48:1–9CrossRefPubMed

27.

Muñoz M, Coveñas R, Esteban F et al (2015) The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci 40:441–463CrossRefPubMed

28.

Muñoz M, González-Ortega A, Rosso M et al (2012) The substance P/Neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 38:318–325CrossRefPubMed

29.

Muñoz M, Pavon A, Rosso M et al (2010) Immunolocalization of NK-1 receptor and substance P in human normal placenta. Placenta 31:649–651CrossRefPubMed

30.

North PE, Waner M, Mizeracki A et al (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11–22CrossRefPubMed

31.

North PE, Waner M, Mizeracki A et al (2001) A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 137:559–570CrossRefPubMed

32.

Samsam M, Coveñas R, Csillik B et al (2001) Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; A possible neurophysiological and neuroanatomical link to generalized head pain. J Chem Neuroanat 21:161–169CrossRefPubMed

33.

Walczak-Drzewiecka A, Ratajewski M, Wagner W et al (2008) HIF1alphais up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J Immunol 181:1665–1672CrossRefPubMed

34.

Wassef M, Blei F, Adams D et al (2015) Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 136:203–214CrossRef

35.

Ziche M, Morbidelli L, Pacini M et al (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264–278CrossRefPubMed

36.

Ziche M, Morbidelli L, Pacini M et al (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036–2044CrossRefPubMedPubMedCentral

Title: Immunolocalization of substance P and NK-1 receptor in vascular anomalies
Authors: Alejandro Ortiz-Prieto
José Bernabeu-Wittel
Teresa Zulueta-Dorado
Ana I. Lorente-Lavirgen
Miguel Muñoz
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 2/2017
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-016-1707-y

At a glance: The STEP trials

Springer Medicine

Immunolocalization of substance P and NK-1 receptor in vascular anomalies

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Senescence in the lesional fibroblasts of non-segmental vitiligo patients

N-Acetylglutaminoyl-S-farnesyl-l-cysteine (SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes

Investigation of 36 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in a psoriatic arthritis cohort

Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets

Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients

In vitro cultured fetal fibroblasts have myofibroblast-associated characteristics and produce a fibrotic-like environment upon stimulation with TGF-β1: Is there a thin line between fetal scarless healing and fibrosis?